ClinicalTrials.gg

Program

catequentinib hydrochloride

Also written as “Anlotinib Hydrochloride Capsules”, “Anlotinib hydrochloride capsule” and “Anlotinib Hydrochloride Capsule”.

Its studies are mostly in Endometrial Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Sarcoma, Alveolar Soft Part, led by Sino Biopharmaceutical.

Furthest: phase 4, since Apr 14, 202320 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical207 open or runningphase 4since Apr 14, 2023Apr 10, 2020Dec 2026phase 3 · NCT04344158

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 10, 2020.

  1. Jul 13, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04964479 · 375 enrolled · China
  2. Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerNCT05068206 · 120 enrolled · China
  3. Nov 15, 2021Phase 2 study in Endometrial NeoplasmsNCT05121363 · 113 enrolled · China
  4. Nov 23, 2021Phase 3 study in Recurrent Platinum-resistant Ovarian CancerNCT05145218 · 405 enrolled · China
  5. Jul 6, 2022Phase 2 study in Advanced Endometrial CancerNCT05481645 · 71 enrolled · China
  6. Sep 27, 2022Phase 1 study in Liver DiseasesNCT05559242 · 30 enrolled · China
  7. Apr 14, 2023Phase 4 study in Carcinoma, MedullaryNCT05830500 · 360 planned · China
  8. May 15, 2023Phase 3 study in Carcinoma, HepatocellularNCT05862337 · 480 planned · China
  9. Jun 13, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05913089 · 58 planned · China
  10. Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaNCT05975645 · 29 enrolled · China
  11. Jun 21, 2024Phase 3 study in Endometrial NeoplasmsNCT06475599 · 420 planned · China
  12. Mar 19, 2025Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06897579 · 40 enrolled · China
  13. Apr 17, 2026Phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177 · 33 planned · China
  14. Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177

Ahead

  1. Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158
  2. Jun 2027Primary completion: phase 4 study in Carcinoma, MedullaryNCT05830500
  3. Dec 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT06475599
  4. Dec 2028Primary completion: phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07548177Sarcoma, Alveolar Soft Part · China2RecruitingDec 202833
NCT06897579Extensive Stage Small Cell Lung Cancer · China2TerminatedApr 15, 202640
NCT06475599Endometrial Neoplasms · China3Not yet recruitingDec 2027420
NCT05975645Advanced Hepatocellular Carcinoma · China1TerminatedJun 4, 202529
NCT05913089Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 202658
NCT05862337Carcinoma, Hepatocellular · China3RecruitingAug 2024480
NCT05830500Carcinoma, Medullary · China4RecruitingJun 2027360
NCT05559242Liver Diseases · China1UNKNOWNJun 202330
NCT05481645Advanced Endometrial Cancer · China2TerminatedFeb 1, 202471
NCT05145218Recurrent Platinum-resistant Ovarian Cancer · China3UNKNOWNOct 2024405
NCT05121363Endometrial Neoplasms · China2UNKNOWNMay 2023113
NCT05068206Unresectable Metastatic Colorectal Cancer · China2UNKNOWNDec 2023120
NCT04964479Carcinoma, Non-Small-Cell Lung · China3UNKNOWNDec 2022375
NCT04924192Advanced Lung Carcinoma · China2TerminatedSep 27, 202221
NCT04854668Colorectal Neoplasms · China3Active, not recruitingDec 31, 2024748
NCT04827004Lymphoma, Large B-Cell, Diffuse · China2UNKNOWNDec 31, 202230
NCT04809142Advanced Biliary Cancer · China3UNKNOWNMar 18, 2022392
NCT04439890Advanced Non-squamous Cell Non-small Cell Lung Cancer · China3UNKNOWNJun 1, 2021369
NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China3UNKNOWNOct 31, 2023528
NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China3Active, not recruitingDec 2026648

How it is read

Names in the registry

  • “Anlotinib Hydrochloride Capsules”, 5 entries
  • “Anlotinib hydrochloride capsule”, 4 entries
  • “Anlotinib Hydrochloride Capsule”, 3 entries
  • “Anlotinib Hydrochloride capsules”, 2 entries
  • “Benmelstobart injection combined with Anlotinib hydrochloride capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.